EMulate Therapeutics Announces the Publication of the Evaluation of Its Ultra-Low Radiofrequency Energy Device in Murine Model of Glioblastoma in BMC Bioelectric Medicine

Written By Kyle Kingma
Kyle Kingma
Previous

EMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma Model
Next

EMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG